Home » The exosome development and manufacturing services market is projected to grow at an annualized rate of ~16%, till 2035

Health & Fitness

The exosome development and manufacturing services market is projected to grow at an annualized rate of ~16%, till 2035

R A

May 2, 2022

Roots Analysis has done a detailed report on Exosome Development and Manufacturing Services Market, 2022-2035, covering key aspects of the industry and identifying key future growth opportunities

To order this 300+ page report, which features 210+ figures and 250+ tables, please visit https://www.rootsanalysis.com/reports/exosome-development-and-manufacturing-services-market.html

Key Market Insights

• Presently, over 45 players, based in different regions of the world claim to offer services for the development and manufacturing of exosomes; most of these players offer services for research purposes
• The current market is fragmented, featuring a mix of both well-established and new firms that offer a wide range of exosome related services
• In pursuit of a competitive edge, stakeholders are actively expanding their existing capabilities to enhance their respective offerings and comply with evolving industry benchmarks
• The rising interest of stakeholders is reflected by the increasing number of partnerships established between various industry and non-industry players for exosome-related services
• Published scientific literature is also indicative of the ongoing research in this field; most of the studies are focused on exosome-based therapeutics and biomarkers
• Both industry and non-industry players have participated in various global events to discuss the research outcomes, and affiliated challenges as well as opportunities
• Innovative exosome technologies developed by various industry players have enabled the drug developers to produce exosomes for disease diagnosis and treatment purposes
• Over the years, more than 9,000 patents have been granted / filed for various exosome technologies, primarily by players based in North America The development of exosomes has been restricted owing to the multiple challenges in their manufacturing, such as heterogeneity of exosomes, optimization of exosome isolation.
• 29,000+ patients have been recruited / enrolled in clinical trials evaluating the exosome related therapies and biomarkers across different geographies
• The market is expected to grow at an annualized rate of 16% between 2022-2035; the opportunity is likely to be well-distributed across different scales of operation and geographies.
• A competitiveness analysis of exosome service providers based on various relevant parameters, such as supplier strength (based on the experience / expertise of the service providers and company size), service strength (number of stages of development (discovery, preclinical, clinical or commercialized), scalability criteria, number of isolation and purification methods, number of characterization methods, number of chromatography techniques, quality control methods and exosome manufacturing methods).

For more information, please visit https://www.rootsanalysis.com/reports/exosome-development-and-manufacturing-services-market.html

Table of Contents

1. PREFACE

1.1.      Scope of the Report

1.2.      Research Methodology

1.3.      Key Questions Answered

1.4.      Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1.      Chapter Overview

3.2.      Types of Extracellular Vesicles

3.2.1.   Apoptotic bodies: An Overview

3.2.2.   Micro vesicles: An Overview

3.2.3.   Exosomes: An Overview

3.3.      Composition of Exosomes

3.4.      Exosome Biogenesis

3.5.      Exosome Development: An Overview

3.5.1.   Methods for Isolation of Exosomes

3.5.2.   Methods for Purification of Exosomes

3.5.3.   Methods for Characterization of Exosomes

3.6.      Manufacturing of Exosomes

3.7.      Outsourcing of Exosomes related Services

3.8.      Therapeutic Applications of Exosomes

3.8.1.   Modification of Immune System

3.8.2.   Exosomes as Targeted Drug Delivery Vehicles

3.8.3.   Engineered Exosomes

3.9.      Challenges Associated with the Development and Manufacturing of Exosomes

3.9.1.   Lack of Standardized Isolation and Purification Methods

3.9.2.   Limited Drug Loading Ability

3.9.3.   Inadequate Clinical Grade Production

3.10.    Future Perspectives

4. EXOSOME SERVICE PROVIDERS: MARKET LANDSCAPE

4.1.      Chapter Overview

4.2.      Exosome Service Providers: Developer Landscape

4.2.1.   Analysis by Year of Establishment

4.2.2.   Analysis by Company Size

4.2.3.   Analysis by Location of Headquarters

4.2.4.   Analysis by Location of Headquarters and Company Size

4.3.      Analysis by Type of Service(s) Offered

4.3.1.   Analysis by Method of Isolation

4.3.2.   Analysis by Method of Purification
4.3.3.   Analysis by Method of Characterization

4.3.4.   Analysis by Method of Exosome Manufacturing

4.3.5.   Analysis by Scale of Operation

4.3.6.   Analysis by Scalability

5. COMPANY COMPETITIVENESS ANALYSIS

5.1.      Chapter Overview

5.2.      Assumptions and Key Parameters

5.3.      Scope and Methodology

5.4.      Company Competitiveness Analysis: Exosome Service Providers in North America

5.5.      Company Competitiveness Analysis: Exosome Service Providers in Europe

5.6.      Company Competitiveness Analysis: Exosome Service Providers in Asia-Pacific and Rest of the World

6. COMPANY PROFILES: EXOSOME SERVICE PROVIDERS

6.1.      Chapter Overview

6.2.      Key Players based in North America

6.2.1.   Creative Bioarray

6.2.1.1. Company Overview

6.2.1.2. Service Portfolio

6.2.1.3. Recent Developments and Future Outlook

6.2.2.   Creative Biolabs

6.2.2.1. Company Overview

6.2.2.2. Service Portfolio

6.2.2.3. Recent Developments and Future Outlook

6.2.3.   Creative Biostructure

6.2.3.1. Company Overview

6.2.3.2. Service Portfolio

6.2.3.3. Recent Developments and Future Outlook

6.3.      Key Players based in Europe

6.3.1.   Amsbio

6.3.1.1. Company Overview

6.3.1.2. Service Portfolio

6.3.1.3. Recent Developments and Future Outlook

6.3.2.   Cambridge Bioscience

6.3.2.1. Company Overview

6.3.2.2. Service Portfolio

6.3.2.3. Recent Developments and Future Outlook

6.3.3.   Lonza

6.3.3.1. Company Overview

6.3.3.2. Financial Information

6.3.3.3. Service Portfolio

6.3.3.4. Manufacturing Facilities

6.3.3.5. Recent Developments and Future Outlook

6.3.4.   Qiagen

6.3.4.1. Company Overview

6.3.4.2. Financial Information

6.3.4.3. Service Portfolio

6.3.4.4. Recent Developments and Future Outlook

6.4.      Key Players based in Asia-Pacific

6.4.1.   Exopharm

6.4.1.1. Company Overview

6.4.1.2. Financial Information

6.4.1.3. Service Portfolio

6.4.1.4. Recent Developments and Future Outlook

6.4.2.   Sumika Chemical Analysis Service

6.4.2.1. Company Overview

6.4.2.2. Service Portfolio

6.4.2.3. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS

7.1.      Chapter Overview

7.2.      Partnership Models

7.3.      Exosome Service Providers: List of Partnerships and Collaborations

7.3.1.   Analysis by Year of Partnership

7.3.2.   Analysis by Type of Partnership

7.3.3.   Analysis by Year and Type of Partnership

7.3.4.   Analysis by Type of Partner

7.3.5.   Analysis by Type of Service Offered

7.3.6.   Word Cloud Analysis: Emerging Focus Areas

7.3.7.   Analysis by Target Disease Indication

7.3.8.   Analysis by Therapeutic Area

7.3.9.   Analysis by Type of Technology

7.3.10.             Most Active Players: Analysis by Number of Partnerships

7.3.11.             Analysis by Type of Service Offered and Type of Partnership

7.3.12.             Analysis by Target Disease Indication and Type of Partnership

7.3.13.             Regional Analysis

7.3.14.             Intercontinental and Intracontinental Agreements

8. PUBLICATION ANALYSIS

8.1.      Chapter Overview

8.2.      Scope and Methodology

8.2.1.   Analysis by Year of Publication

8.2.2.   Analysis by Type of Service Offered

8.2.3.   Word Cloud Analysis: Emerging Focus Areas

8.2.4.   Popular Journals: Analysis by Number of Publications

8.2.5.   Popular Journals: Analysis by Journal Impact Factor

9. GLOBAL EVENT ANALYSIS

9.1.      Chapter Overview

9.2.      Scope and Methodology

9.3.      List of Global Events Related to Exosomes

9.3.1.   Analysis by Year of Event

9.3.2.   Analysis by Event Platform

9.3.3.   Analysis by Type of Event

9.3.4.   Analysis by Location of Event

9.3.5.   Word Cloud: Evolutionary Trends in Event Agenda / Key Focus Area

9.3.6.   Most Active Organizers: Analysis by Number of Events

9.3.7.   Most Active Industry Participants: Analysis by Number of Events

9.3.8.   Most Active Non-Industry Participants: Analysis by Number of Events

9.3.9.   Analysis by Designation of Participant

9.3.10.             Analysis by Affiliated Department of Participant

9.3.11.             Most Active Speakers: Analysis by Number of Events

9.3.12.             Geographical Mapping of Upcoming Events

10. EXOSOME BASED TECHNOLOGIES: MARKET OVERVIEW

10.1.    Chapter Overview

10.2.    Exosome Technologies: An Overview

10.3.    List of Exosome Technology Providers

10.3.1.             Exosome Technology Providers: Analysis by Year of Establishment

10.3.2.             Exosome Technology Providers: Analysis by Company Size

10.3.3.  Exosome Technology Providers: Analysis by Location of Headquarters

10.4.    Exosome Technologies: Information of Technology Related Services and Therapeutic Applications

10.4.1.             Summary

11. PATENT ANALYSIS

11.1.    Chapter Overview

11.2.    Scope and Methodology

11.3.    Exosomes Technologies: Patent Analysis

11.3.1.             Analysis by Type of Patent

11.3.2.             Analysis by Publication Year

11.3.3.             Analysis by Application Year

11.3.4.             Analysis by Geographical Location

11.3.5.             Analysis by CPC Symbols

11.3.6.             Word Cloud Analysis: Emerging Focus Areas

11.3.7.             Analysis Type of Organization

11.3.8.             Leading Industry Players: Analysis by Number of Patents

11.3.9.             Leading Non-Industry Players: Analysis by Number of Patents

11.3.10.Leading Patent Assignees: Analysis by Number of Patents

11.4.    Exosome Technologies: Patent Benchmarking Analysis

11.4.1.             Analysis by Patent Characteristics (CPC Symbols)

11.5.    Analysis of Patents by Age

11.6.    Patent Valuation Analysis

11.7.    Leading Patents by Number of Citations

12. CLINICAL TRIAL ANALYSIS

12.1.    Chapter Overview

12.2.    Scope and Methodology

12.3.    Analysis by Trial Status

12.4.    Analysis by Trial Registration Year

12.5.    Analysis by Trial Registration Year and Enrolled Patient Population

12.6.    Analysis by Trial Recruitment Status

12.7.    Analysis by Trial Phase and Number of Patients Enrolled

12.8.    Analysis by Study Design

12.9.    Analysis by Type of Sponsor / Collaborator

12.10. Leading Players: Analysis by Number of Registered Trials

12.11. Word Cloud Analysis: Emerging Focus Areas

12.12. Geographical Analysis by Number of Registered Trails

12.13. Geographical Analysis by Enrolled Patient Population

13. MARKET FORECAST

13.1.    Chapter Overview

13.2.    Forecast Methodology and Key Assumptions

13.3.    Exosome Development and Manufacturing Services: Technology Licensing Model

13.4.    Global Exosome Development and Manufacturing Services Market, 2022-2035

13.4.1.             Global Exosome Development and Manufacturing Services Market: Distribution by Stage of Application, 2022 and 2035

13.4.1.1. Global Exosome Development and Manufacturing Services Market for Discovery / Preclinical             Stage

13.4.1.2. Global Exosome Development and Manufacturing Services Market for Clinical Stage

13.4.2.             Global Exosome Development and Manufacturing Services Market: Distribution by Region, 2022 and 2035

13.4.2.1. Exosome Development and Manufacturing Services Market in North America, 2022-2035

13.4.2.2. Exosome Development and Manufacturing Services Market in Europe, 2022-2035

13.4.2.3. Exosome Development and Manufacturing Services Market in Asia Pacific, 2022-2035

13.4.2.4. Exosome Development and Manufacturing Services Market in Rest of the World, 2022-2035

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS

15.1.    Chapter Overview

15.2.    EVerZom

15.2.1.             Company Snapshot

15.2.2.             Interview Transcript: Nicolas Rousseau, Chief Compliance Officer and Co- founder

15.3.    RoosterBio

15.3.1. Company Snapshot

15.3.2.             Interview Transcript: Jonathan Carson, Strategic Marketing Manager

15.4.    Clara Biotech

15.4.1.             Company Snapshot

15.4.2.             Interview Transcript: Navdeep Singh, Product Manager and Technical Lead

16. APPENDIX 1: LIST OF FIGURES AND TABLES

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

Facebook – https://www.facebook.com/RootsAnalysis

LinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter – https://twitter.com/RootsAnalysis

Medium – https://medium.com/@RootsAnalysis

Pinterest – https://in.pinterest.com/RootsanalysisPin/_saved/

Quora – https://rootsanalysisinsights.quora.com/